NBE Therapeutics' unique selling proposition (USP) in the field of Antibody Drug Conjugate (ADC) Development lies in the combination of know-how and technologies available in a single Biotech start-up entity. The majority of players in the ADC field mostly cover one or two aspects of ADC development, e.g. a conjugation approach or a novel toxin, which requires partnering and licenses to access the missing aspects of an ADC. Since incorporation, NBE-Therapeutics has pursued its vision to develop enabling and proprietary technologies allowing NBE-Therapeutics and its partners to address all aspects of ADC discovery and development.
Except for target research and validation, which is covered by academic partnerships, NBE-Therapeutics is uniquely positioned to develop novel, first- and best-in-class ADCs against any desired cancer cell target.
As a result of these capabilities, the intellectual property portfolio of the company covers technology platforms as well as novel composition of matter of therapeutic antibodies and ADCs.
- Basel, 2017-11-28 - NBE-Therapeutics appoints Dr. Nicole Onetto to its Board of Directors
- Lisbon, Portugal, 2017-11-14 - NBE-Therapeutics presented update on R&D activities at 2017-PEGS conference
- Basel, Switzerland, 2017-11-02 - NBE-Therapeutics presented update on R&D activities at 2017 HPAPI World Congress